Antisense Therapy for Infectious Diseases

Area of Science:

• Microbiology
• Molecular Biology
• Pharmacology

Background:

• Infectious diseases, especially Tuberculosis (TB), represent a major global health burden, causing 1.6 million deaths in 2021.
• The increasing prevalence of drug-resistant pathogens necessitates novel therapeutic strategies.
• Antisense therapy, utilizing antisense oligonucleotides (ASOs), offers targeted gene inhibition at the mRNA level.

Purpose of the Study:

• To review the potential of FDA-approved and preclinical antisense oligonucleotides (ASOs) for treating infectious diseases.
• To explore the chemical modifications of ASOs for enhanced efficacy and reduced toxicity.
• To highlight the therapeutic applications of ASOs in combating infectious diseases.

Main Methods:

• Literature review of existing studies on antisense oligonucleotides (ASOs) in infectious disease treatment.
• Analysis of preclinical and FDA-approved ASO data.
• Evaluation of ASO chemical modifications and their impact on drug delivery and side effects.

Main Results:

• Antisense therapy demonstrates specificity in targeting disease-causing genes.
• ASOs are adaptable to chemical modifications, improving drug delivery and minimizing adverse effects.
• Growing evidence supports the potential of ASOs as a viable treatment for various infectious diseases.

Conclusions:

• Antisense oligonucleotides (ASOs) present a promising therapeutic avenue for infectious diseases, including TB.
• The adaptability of ASOs for chemical modifications enhances their safety and efficacy profiles.
• Further research and development of ASOs could lead to new interventions against drug-resistant infections.